Clinical Trials

Source: CCM

Score: 15
Melanoma
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
Score: 14
Liver Cancer, Lung Cancer, Melanoma, Gynecological Cancers
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Score: 13
Phase 1 Cancers
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
Score: 12
Phase 1 Cancers
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors
Score: 11
Phase 1 Cancers
Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors
Score: 10
Infectious Disease
Immune signatures of vaccine responses in vulnerable populations: Comparison of influenza vaccines
- Ages21 years and older
- GenderBoth
Score: 9
Colorectal Cancer, Pancreatic Cancer
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors
Score: 8
Phase 1 Cancers
An Open-Label Study of GV20-0251 in Patients With Advanced and/or Refractory Solid Tumor Malignancies
Score: 7
Phase 1 Cancers
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Score: 6
Phase 1 Cancers
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours